Article Information
History
- October 11, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Noah Kiwanuka*,1,
- Alex Kityamuwesi*,2,
- Rebecca Crowder3,
- Kevin Guzman4,
- Christopher A. Berger3,
- Maureen Lamunu2,
- Catherine Namale2,
- Lynn Kunihira Tinka2,
- Agnes Sanyu Nakate2,
- Joseph Ggita2,
- Patricia Turimumahoro2,
- Diana Babirye2,
- Denis Oyuku2,
- Devika Patel5,
- Amanda Sammann5,
- Turyahabwe Stavia6,
- David Dowdy7,
- Achilles Katamba^,2,8 and
- Adithya Cattamanchi^,2,3,#
- 1Department of Epidemiology & Biostatistics, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda
- 2Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda
- 3San Francisco General Hospital, Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, USA
- 4University of California, Department of Medicine
- 5Zuckerberg San Francisco General Hospital, Department of Surgery, University of California, San Francisco, USA
- 6Uganda National Tuberculosis and Leprosy Programme, Kampala, Uganda
- 7Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA
- 8Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- ↵#CORRESPONDING AUTHOR:
Adithya Cattamanchi, University of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, 1001 Potrero Avenue, Rm 5K1, San Francisco, CA 94110-0111, Email: Adithya.cattamanchi{at}ucsf.edu
Posted October 11, 2022.
Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda
